Short Interest in Catheter Precision, Inc. (NYSEAMERICAN:VTAK) Expands By 91.9%

Catheter Precision, Inc. (NYSEAMERICAN:VTAK) saw a significant growth in short interest in April. As of April 15th, there was short interest totaling 80,782 shares, a growth of 91.9% from the March 31st total of 42,085 shares. Approximately 3.2% of the shares of the stock are sold short. Based on an average daily trading volume, of 306,942 shares, the short-interest ratio is presently 0.3 days.

Institutional Inflows and Outflows

An institutional investor recently bought a new position in Catheter Precision stock. Millennium Management LLC purchased a new position in shares of Catheter Precision, Inc. (NYSEAMERICAN:VTAK) during the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor purchased 34,721 shares of the company’s stock, valued at approximately $64,000. Millennium Management LLC owned 2.08% of Catheter Precision as of its most recent SEC filing. 20.34% of the stock is currently owned by institutional investors.

Catheter Precision Stock Performance

Catheter Precision stock opened at $0.93 on Monday. The company has a debt-to-equity ratio of 0.46, a quick ratio of 0.08 and a current ratio of 0.10. The stock has a fifty day moving average of $1.26 and a two-hundred day moving average of $1.84. The company has a market capitalization of $2.50 million, a price-to-earnings ratio of -0.05 and a beta of -1.17. Catheter Precision has a fifty-two week low of $0.79 and a fifty-two week high of $15.68.

Catheter Precision Company Profile

Catheter Precision, Inc (NYSE American: VTAK) is a medical device company specializing in the design, development and manufacture of catheter-based products for interventional cardiology and peripheral vascular procedures. The company’s core business centers on balloon catheter platforms, offering both standard and specialty catheter configurations that address applications ranging from percutaneous transluminal angioplasty (PTA) to percutaneous transluminal coronary angioplasty (PTCA). Catheter Precision’s product portfolio is engineered to meet diverse clinical needs, including high-pressure dilation, scored and cutting balloon therapies, and drug-coated balloon delivery.

All of Catheter Precision’s products are developed in its ISO 13485-certified, FDA-registered manufacturing facility in Bloomington, Minnesota.